Perspective Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen initiated coverage of Perspective Therapeutics with an Overweight rating. Perspective Therapeutics has a robust pipeline with multiple near-term data readouts and is a fully integrated radiopharma company advancing potentially best- or first-in-class alpha-particle therapies, the analyst tells investors in a research note. Perspective stands out above the competition where it matters, Cantor argues, adding that positive data for VMT01 could open up a large market opportunity. The stock looks undervalued based on recent M&A activity, the firm adds.